{
  "trial_id": "NCT01288339",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Man or woman \u2265 18 years.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Competent to comprehend, sign, and date an IEC-approved (Ethics Committee) informed consent form",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Histologically-confirmed metastatic adenocarcinoma of the colon or rectum by the investigator.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Wild Type K-RAS colorectal cancer determined by the designated Central Laboratory",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "At least 1 uni-dimensionally measurable lesion of at least > 10 mm with spiral CT per modified RECIST criteria 1.1.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or capecitabine +/- radiotherapy with a disease-free interval > than 6 months after its completion.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "De novo diagnosis of the disease.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Eastern Cooperative Oncology Group performance status of 0 or 1.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Life expectancy \u2265 3 months",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Adequate bone marrow function",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Adequate Hepatic and metabolic functions",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Adequate Renal function",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients they have received prior systemic therapy for the treatment of metastatic colorectal carcinoma.",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib) or EGFR signal transduction inhibitors.",
      "label": "triggers",
      "evidence": ""
    }
  ],
  "notes": "Patient has metastatic papillary thyroid cancer and has received XRT to the neck. They have a history of basal cell carcinoma of the skin.",
  "_meta": {
    "topic_id": "11",
    "trial_id": "NCT01288339",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}